Vatelizumab
N
Y (what is this?) (verify) Vatelizumab is an immunomodulator. It binds to integrin alpha 2.[1]
It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy.[2]
References
- ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
- ^ Mozaffari S, Nikfar S, Abdollahi M (2015). "Inflammatory bowel disease therapies discontinued between 2009 and 2014". Expert Opin Investig Drugs. 24 (7): 949–56. doi:10.1517/13543784.2015.1035432. PMID 25861835. S2CID 26104155.
- v
- t
- e
Monoclonal antibodies for the immune system
| Human | |
|---|---|
| Humanized | |
| Veterinary |
| Mouse |
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
